- Home
- PROK vs BRW Comparison
PROK vs BRW Comparison
Compare PROK & BRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- BRW
- Stock Information
- Founded
- PROK 2015
- BRW 1987
- Country
- PROK United States
- BRW United States
- Employees
- PROK N/A
- BRW N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- BRW Trusts Except Educational Religious and Charitable
- Sector
- PROK Health Care
- BRW Finance
- Exchange
- PROK Nasdaq
- BRW Nasdaq
- Market Cap
- PROK 384.2M
- BRW 354.7M
- IPO Year
- PROK N/A
- BRW N/A
- Fundamental
- Price
- PROK $2.35
- BRW $8.38
- Analyst Decision
- PROK Buy
- BRW
- Analyst Count
- PROK 5
- BRW 0
- Target Price
- PROK $6.25
- BRW N/A
- AVG Volume (30 Days)
- PROK 3.3M
- BRW 222.1K
- Earning Date
- PROK 08-12-2025
- BRW 01-01-0001
- Dividend Yield
- PROK N/A
- BRW 15.59%
- EPS Growth
- PROK N/A
- BRW N/A
- EPS
- PROK N/A
- BRW N/A
- Revenue
- PROK $527,000.00
- BRW N/A
- Revenue This Year
- PROK $105.79
- BRW N/A
- Revenue Next Year
- PROK N/A
- BRW N/A
- P/E Ratio
- PROK N/A
- BRW N/A
- Revenue Growth
- PROK N/A
- BRW N/A
- 52 Week Low
- PROK $0.46
- BRW $7.15
- 52 Week High
- PROK $7.13
- BRW $8.30
- Technical
- Relative Strength Index (RSI)
- PROK 43.77
- BRW 58.72
- Support Level
- PROK $2.16
- BRW $8.24
- Resistance Level
- PROK $2.46
- BRW $8.42
- Average True Range (ATR)
- PROK 0.34
- BRW 0.08
- MACD
- PROK -0.16
- BRW -0.02
- Stochastic Oscillator
- PROK 7.14
- BRW 56.00
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.